Global Blood Therapeutics (GBT) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
GBT Reports Second Quarter 2021 Financial Results
August 3, 2021 4:05 PM EDTAchieved Oxbryta® (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year
Continued progress toward potential Oxbryta pediatric label expansion in U.S. and marketing authorization in Europe  Â
Advanced pipeline with initiation of two inclacumab pivotal Phase 3 trials and GBT021601 (GBT601) Phase 1 trial  Conference call today at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported financial results for the second quarter ended June 30, 2021 and... More
